JP7483620B2 - Ｗｅｅ１キナーゼ阻害物質およびそれを使用してがんを処置する方法 - Google Patents

Ｗｅｅ１キナーゼ阻害物質およびそれを使用してがんを処置する方法 Download PDF

Info

Publication number
JP7483620B2
JP7483620B2 JP2020545351A JP2020545351A JP7483620B2 JP 7483620 B2 JP7483620 B2 JP 7483620B2 JP 2020545351 A JP2020545351 A JP 2020545351A JP 2020545351 A JP2020545351 A JP 2020545351A JP 7483620 B2 JP7483620 B2 JP 7483620B2
Authority
JP
Japan
Prior art keywords
mmol
compound
wee1
alkyl
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020545351A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021516231A (ja
JPWO2019169065A5 (https=
JP2021516231A5 (https=
Inventor
フィリップ レイガン
ドナルド エス． バッコス
クリストファー ジェイ． マチソン
キンバリー エイ． カザルヴィエーリ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Colorado Colorado Springs
Original Assignee
University of Colorado Colorado Springs
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Colorado Colorado Springs filed Critical University of Colorado Colorado Springs
Publication of JP2021516231A publication Critical patent/JP2021516231A/ja
Publication of JPWO2019169065A5 publication Critical patent/JPWO2019169065A5/ja
Publication of JP2021516231A5 publication Critical patent/JP2021516231A5/ja
Application granted granted Critical
Publication of JP7483620B2 publication Critical patent/JP7483620B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2020545351A 2018-02-28 2019-02-28 Ｗｅｅ１キナーゼ阻害物質およびそれを使用してがんを処置する方法 Active JP7483620B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862636831P 2018-02-28 2018-02-28
US62/636,831 2018-02-28
PCT/US2019/019936 WO2019169065A2 (en) 2018-02-28 2019-02-28 Wee1 kinase inhibitors and methods of treating cancer using the same

Publications (4)

Publication Number Publication Date
JP2021516231A JP2021516231A (ja) 2021-07-01
JPWO2019169065A5 JPWO2019169065A5 (https=) 2022-03-09
JP2021516231A5 JP2021516231A5 (https=) 2022-03-09
JP7483620B2 true JP7483620B2 (ja) 2024-05-15

Family

ID=67805580

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020545351A Active JP7483620B2 (ja) 2018-02-28 2019-02-28 Ｗｅｅ１キナーゼ阻害物質およびそれを使用してがんを処置する方法

Country Status (6)

Country Link
US (2) US12220415B2 (https=)
EP (1) EP3758706A4 (https=)
JP (1) JP7483620B2 (https=)
AU (1) AU2019227823B2 (https=)
CA (1) CA3088997A1 (https=)
WO (1) WO2019169065A2 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6692423B2 (ja) 2015-11-01 2020-05-13 ザ リージェンツ オブ ザ ユニヴァーシティ オブ コロラド，ア ボディ コーポレイト Ｗｅｅ１キナーゼ阻害剤、並びにそれを作製及び使用する方法
WO2019018584A1 (en) 2017-07-18 2019-01-24 GiraFpharma LLC HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS
EP3654982A4 (en) 2017-07-18 2021-04-14 Nuvation Bio Inc. 1,8-NAPHTHYRIDINONE COMPOUNDS AND THEIR USES
WO2019074979A1 (en) 2017-10-09 2019-04-18 Girafpharma, Llc HETEROCYCLIC COMPOUNDS AND USES THEREOF
US10807994B2 (en) 2017-10-09 2020-10-20 Nuvation Bio Inc. Heterocyclic compounds and uses thereof
EP3758706A4 (en) 2018-02-28 2021-11-24 The Regents Of The University Of Colorado WEE1 KINASE INHIBITORS AND METHODS OF TREATING CANCER USING THEREOF
MX2020009372A (es) 2018-03-09 2020-10-14 Recurium Ip Holdings Llc 1,2-dihidro-3h-pirazolo[3,4-d]pirimidin-3-onas sustituidas.
EP3911323A4 (en) 2019-01-18 2022-11-16 Nuvation Bio Inc. HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS
EP3911324A4 (en) 2019-01-18 2022-08-17 Nuvation Bio Inc. 1,8-NAPHTHYRIDINONE COMPOUNDS AND THEIR USES
CN113939296A (zh) 2019-04-09 2022-01-14 诺维逊生物股份有限公司 杂环化合物及其用途
MX2022007623A (es) * 2019-12-20 2022-09-23 Recurium Ip Holdings Llc Combinaciones.
AU2020404995A1 (en) * 2019-12-20 2022-07-14 Recurium Ip Holdings, Llc Combinations
CN113402520A (zh) * 2020-03-16 2021-09-17 中国科学院上海药物研究所 Wee1蛋白降解剂
US12522607B2 (en) 2020-06-17 2026-01-13 Wigen Biomedicine Technology (shanghai) Co., Ltd. Substituted pyrazolo[3,4-d]pyrimidines as wee-1 inhibitors
JP2024520969A (ja) * 2021-05-28 2024-05-28 江蘇天士力帝益薬業有限公司 Ｗｅｅ１阻害剤とその用途
WO2023107705A1 (en) 2021-12-10 2023-06-15 Incyte Corporation Bicyclic amines as cdk12 inhibitors

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006091737A1 (en) 2005-02-24 2006-08-31 Kemia, Inc. Modulators of gsk-3 activity
WO2007126122A1 (en) 2006-04-27 2007-11-08 Banyu Pharmaceutical Co., Ltd. Dihydropyrazolopyrimidinone derivatives
JP2013503859A (ja) 2009-09-02 2013-02-04 オークランド ユニサーヴィスィズ リミテッド キナーゼインヒビター、そのプロドラッグ型および治療におけるそれらの使用
WO2017075629A2 (en) 2015-11-01 2017-05-04 The Regents Of The University Of Colorado, A Body Corporate Wee 1 kinase inhibitors and methods of making and using the same
WO2018133829A1 (zh) 2017-01-23 2018-07-26 南京明德新药研发股份有限公司 作为Wee1抑制剂的1,2-二氢-3H-吡唑[3,4-d]嘧啶-3-酮衍生物
WO2019028008A1 (en) 2017-08-01 2019-02-07 Zeno Royalties & Milestones, LLC 1,2-DIHYDRO-3H-PYRAZOLO [3,4-D] PYRIMIDIN-3-ONE ANALOGUES

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB884151A (en) * 1957-12-06 1961-12-06 Ciba Ltd New pyrazolo-pyrimidines substituted in the pyrazole nucleus, and process for their manufacture
NZ620000A (en) * 2009-03-11 2015-07-31 Auckland Uniservices Ltd Prodrug forms of kinase inhibitors and their use in cancer therapy
GB201322602D0 (en) 2013-12-19 2014-02-05 Almac Discovery Ltd Pharmaceutical compounds
CN108341830B (zh) 2017-01-22 2021-03-02 广东东阳光药业有限公司 噻吩并嘧啶衍生物及其在药物中的应用
EP3758706A4 (en) 2018-02-28 2021-11-24 The Regents Of The University Of Colorado WEE1 KINASE INHIBITORS AND METHODS OF TREATING CANCER USING THEREOF

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006091737A1 (en) 2005-02-24 2006-08-31 Kemia, Inc. Modulators of gsk-3 activity
WO2007126122A1 (en) 2006-04-27 2007-11-08 Banyu Pharmaceutical Co., Ltd. Dihydropyrazolopyrimidinone derivatives
WO2007126128A1 (ja) 2006-04-27 2007-11-08 Banyu Pharmaceutical Co., Ltd. ジヒドロピラゾロピリミジノン誘導体
JP2013503859A (ja) 2009-09-02 2013-02-04 オークランド ユニサーヴィスィズ リミテッド キナーゼインヒビター、そのプロドラッグ型および治療におけるそれらの使用
WO2017075629A2 (en) 2015-11-01 2017-05-04 The Regents Of The University Of Colorado, A Body Corporate Wee 1 kinase inhibitors and methods of making and using the same
WO2018133829A1 (zh) 2017-01-23 2018-07-26 南京明德新药研发股份有限公司 作为Wee1抑制剂的1,2-二氢-3H-吡唑[3,4-d]嘧啶-3-酮衍生物
WO2019028008A1 (en) 2017-08-01 2019-02-07 Zeno Royalties & Milestones, LLC 1,2-DIHYDRO-3H-PYRAZOLO [3,4-D] PYRIMIDIN-3-ONE ANALOGUES

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Jiayi Shen et al.，3-aminopyrazolopyrazine derivatives as spleen tyrosine kinase inhibitors，Chemical biology & Drug Design，2016年06月06日，Volume 88, Isuue 5，pp. 690-698
MARTIN HAUSER et al.，Pyrazolono(3,4-d)pyrimidines. II. 6-Methylpyrazolono(3,4-d)pyrimidines and Some Reactions of Pyrazolono(3,4-d)pyrimidines，The Jpurnal of Organic Chemistry，1961年02月01日，Volume 26, Issue 2，pp. 451-455
Moana Tercel et al.，Hypoxia-Selective Antitumor Agents. 16. Nitroarylmethyl Quaternary Salts as Bioreductive Prodrugs of the Alkylating Agent Mechlorethamine，Journal of Medicinal Chemistry，2001年09月13日，Volume 44, Issue 21，pp. 3511-3522
Organic & Biomolecular Chemistry，Current molecular design of intelligent drugs and imaging probes targeting tumor-specific microenvironments，Kazuhito Tanabe et al.，2007年10月01日，Volume 5, Issue 23，pp. 3745-3757

Also Published As

Publication number Publication date
JP2021516231A (ja) 2021-07-01
CA3088997A1 (en) 2019-09-06
AU2019227823A1 (en) 2020-08-06
US20250186447A1 (en) 2025-06-12
EP3758706A2 (en) 2021-01-06
WO2019169065A2 (en) 2019-09-06
US20200405723A1 (en) 2020-12-31
AU2019227823B2 (en) 2024-12-12
WO2019169065A3 (en) 2020-04-30
EP3758706A4 (en) 2021-11-24
US12220415B2 (en) 2025-02-11

Similar Documents

Publication Publication Date Title
JP7483620B2 (ja) Ｗｅｅ１キナーゼ阻害物質およびそれを使用してがんを処置する方法
JP6692423B2 (ja) Ｗｅｅ１キナーゼ阻害剤、並びにそれを作製及び使用する方法
US11999731B2 (en) EGFR dimer disruptors and use of the same
CN105008351B (zh) Cdc7抑制剂
US9073916B2 (en) Prodrug forms of kinase inhibitors and their use in therapy
JP7320823B2 (ja) プテリジノン誘導体のｅｇｆｒ阻害剤としての使用
US9238654B2 (en) Singleton inhibitors of sumoylation enzymes and methods for their use
AU2019202922A1 (en) Compositions and methods of using the same for treatment of neurodegenerative and mitochondrial disease
KR20220050143A (ko) Kras-관련 암 치료 방법
KR102029135B1 (ko) 암 및 관련 질병 및 상태 치료용 중수소화된 화합물, 그의 조성물 및 방법
CA3172987A1 (en) Small molecule inhibitors of oncogenic chd1l with preclinical activity against colorectal cancer
EP2531032B1 (en) Materials and method for inhibiting replication protein a and uses thereof
US12570651B2 (en) Quinazoline-2,4-dione derivatives as PARP inhibitors
US20190117663A1 (en) Compositions and methods for treating cancer
US9750742B2 (en) Small molecular inhibitors of RAD51 recombinase and methods thereof
US8293764B2 (en) Compositions and methods for disruption of BRCA2-Rad51 interaction
US20250129083A1 (en) Imidazotetrazine compounds and treatment of tmz-resistant cancers
WO2025087941A1 (en) Parg inhibitors in combination with parp inhibitors and uses thereof
EP4446320A1 (en) Novel heterocyclic-substituted pyrimidine derivative exhibiting cancer cell growth inhibitory effect, and pharmaceutical composition containing same
CN118355012A (zh) 表现出癌细胞生长抑制效果的新型杂环取代嘧啶衍生物以及含有其的药物组合物
CN120513251A (zh) 肿瘤氧化还原激活的含6-硫代嘌呤的二聚体化合物
HK1261379B (en) Deuterated compounds for treating cancer and compositions and methods thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201118

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20210414

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220228

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220228

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230222

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230327

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230626

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20230627

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230926

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20231102

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240226

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20240304

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240409

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240501

R150 Certificate of patent or registration of utility model

Ref document number: 7483620

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150